Connect
← Return to Negative Turn in a Long Journey
Discussion
Negative Turn in a Long Journey
Pancreatic Cancer | Last Active: Oct 1 5:03pm | Replies (102)Comment receiving replies
Since your CA 19-9 is not necessarily predictive, I might suggest asking your doctors to do the Signatera blood test by Natera. New so that when my scans are clear. It lets us know something is brewing.
My pancreas tumor has been gone since 2022 but we still relate emerging tumors to metastases since the little cowboys can hide for quite awhile before they decide to post up somewhere.
Among other things I am now looking for a blood test for mutations. A recent tissue biopsy was unsuccessful but I am interested to know if I have now experienced further mutations after all this. My known or KRAS G12D and TP53 but my doctor says it is likely there could be a new mutation.
Replies to "Since your CA 19-9 is not necessarily predictive, I might suggest asking your doctors to do..."
Connect
Thanks for the advice @gamaryanne. I will keep the Signatera test on my radar; I have had Foundation and Tempus liquid biopsies done in the past. I'm waiting to see what type of testing they will do once I start the trial then go from there.
Just heard that the trial approval by Yale should be done tomorrow and I will sign the paperwork needed on Friday to officially get started. I still have to get a baseline CT scan scheduled but hopefully by the week of the 11th at the latest, I'll get started on the actual trial drug. Next thing I wish I knew now is which arm of the trial I will be in: one arm is just the drug (QTX-3034) but the other arm combines it with Cetuximab, which I know little or nothing about.